Literature DB >> 19416302

The effects of steroids during sepsis depend on dose and severity of illness: an updated meta-analysis.

P C Minneci1, K J Deans, P Q Eichacker, C Natanson.   

Abstract

A previous meta-analysis determined that the effects of steroids during sepsis were dose-dependent; since then, additional trials have been published. The current analysis updates our previous analysis examining the effects of steroids during sepsis. A literature search from 2004 to 2008 identified seven randomized controlled trials in adult patients; these were added to 14 previously identified trials. The effects of steroids on mortality were highly variable among the 21 trials (p <0.001, I(2) = 60%). In trials published before 1989, which involved short courses of high-dose steroids, steroids increased mortality (n = 8, I(2) = 14%, OR of death 1.39 (95% CI 1.04-1.86), p 0.03). In trials published after 1997, which involved longer courses of lower-dose steroids, steroids consistently improved shock reversal (n = 7, I(2) = 0%, OR of shock reversal 1.66 [95% CI 1.25-2.20), p <0.001), but demonstrated a more heterogeneous beneficial effect on mortality (n = 12, I(2) = 25%, OR of death 0.64 (95% CI 0.45-0.93), p 0.02). An inverse linear relationship between severity of illness and the effects of steroids on mortality was identified across all trials (p 0.03) and within the subgroup of trials published after 1997 (p 0.03); steroids were harmful in less severely ill patient populations and beneficial in more severely ill patient populations. There was no effect of response to adrenocorticotrophic hormone (ACTH) stimulation testing concerning the effects of steroids and no increase in steroid-associated adverse events. Low-dose steroids appear to improve mortality rates in patients with septic shock who are at high risk of death; however, additional trials in this subpopulation are necessary to definitively determine the role of low-dose steroids during sepsis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19416302      PMCID: PMC3383780          DOI: 10.1111/j.1469-0691.2009.02752.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  43 in total

Review 1.  Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials.

Authors:  Peter Q Eichacker; Charles Natanson
Journal:  Crit Care Med       Date:  2003-01       Impact factor: 7.598

Review 2.  Measuring inconsistency in meta-analyses.

Authors:  Julian P T Higgins; Simon G Thompson; Jonathan J Deeks; Douglas G Altman
Journal:  BMJ       Date:  2003-09-06

3.  Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.

Authors:  D C Angus; W T Linde-Zwirble; J Lidicker; G Clermont; J Carcillo; M R Pinsky
Journal:  Crit Care Med       Date:  2001-07       Impact factor: 7.598

4.  Once is not enough: clinical trials in sepsis.

Authors:  Daniel A Sweeney; Robert L Danner; Peter Q Eichacker; Charles Natanson
Journal:  Intensive Care Med       Date:  2008-10-07       Impact factor: 17.440

5.  Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis.

Authors:  Peter Q Eichacker; Chantal Parent; Andre Kalil; Claire Esposito; Xizhong Cui; Steven M Banks; Eric P Gerstenberger; Yvonne Fitz; Robert L Danner; Charles Natanson
Journal:  Am J Respir Crit Care Med       Date:  2002-11-01       Impact factor: 21.405

6.  Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.

Authors:  B L Warren; A Eid; P Singer; S S Pillay; P Carl; I Novak; P Chalupa; A Atherstone; I Pénzes; A Kübler; S Knaub; H O Keinecke; H Heinrichs; F Schindel; M Juers; R C Bone; S M Opal
Journal:  JAMA       Date:  2001-10-17       Impact factor: 56.272

7.  Measurements of serum free cortisol in critically ill patients.

Authors:  Amir H Hamrahian; Tawakalitu S Oseni; Baha M Arafah
Journal:  N Engl J Med       Date:  2004-04-15       Impact factor: 91.245

8.  Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.

Authors:  Edward Abraham; Konrad Reinhart; Steven Opal; Ignace Demeyer; Christopher Doig; Angel López Rodriguez; Richard Beale; Petr Svoboda; Pierre Francois Laterre; Stuart Simon; Bruce Light; Herbert Spapen; Judy Stone; Allan Seibert; Claus Peckelsen; Cathy De Deyne; Russell Postier; Ville Pettilä; Charles L Sprung; Antonio Artigas; Sandra R Percell; Vincent Shu; Christian Zwingelstein; Jeffrey Tobias; Lona Poole; James C Stolzenbach; Abla A Creasey
Journal:  JAMA       Date:  2003-07-09       Impact factor: 56.272

9.  Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.

Authors:  Djillali Annane; Véronique Sébille; Claire Charpentier; Pierre-Edouard Bollaert; Bruno François; Jean-Michel Korach; Gilles Capellier; Yves Cohen; Elie Azoulay; Gilles Troché; Philippe Chaumet-Riffaud; Philippe Chaumet-Riffaut; Eric Bellissant
Journal:  JAMA       Date:  2002-08-21       Impact factor: 56.272

10.  Physiological-dose steroid therapy in sepsis [ISRCTN36253388].

Authors:  Orhan Yildiz; Mehmet Doganay; Bilgehan Aygen; Muhammet Güven; Fahrettin Keleştimur; Ahmet Tutuû
Journal:  Crit Care       Date:  2002-04-19       Impact factor: 9.097

View more
  37 in total

Review 1.  The evolving experience with therapeutic TNF inhibition in sepsis: considering the potential influence of risk of death.

Authors:  Ping Qiu; Xizhong Cui; Amisha Barochia; Yan Li; Charles Natanson; Peter Q Eichacker
Journal:  Expert Opin Investig Drugs       Date:  2011-10-01       Impact factor: 6.206

2.  Effect of high dose of steroid on plateletcount in acute stage of dengue Fever with thrombocytopenia.

Authors:  K C Shashidhara; K A Sudharshan Murthy; H Basavana Gowdappa; Abhijith Bhograj
Journal:  J Clin Diagn Res       Date:  2013-07-01

3.  Steroids for sepsis: yes, no or maybe.

Authors:  Paul E Marik
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

4.  Beneficial effects of stress-dose corticosteroid therapy in canines depend on the severity of staphylococcal pneumonia.

Authors:  Caitlin W Hicks; Daniel A Sweeney; Robert L Danner; Peter Q Eichacker; Anthony F Suffredini; Jing Feng; Junfeng Sun; Brad Moriyama; Robert Wesley; Ellen N Behrend; Steven B Solomon; Charles Natanson
Journal:  Intensive Care Med       Date:  2012-10-31       Impact factor: 17.440

5.  Complicated Weil Disease.

Authors:  Vitorino Modesto Dos Santos
Journal:  Balkan Med J       Date:  2016-07-01       Impact factor: 2.021

Review 6.  Targeting inflammation to prevent bronchopulmonary dysplasia: can new insights be translated into therapies?

Authors:  Clyde J Wright; Haresh Kirpalani
Journal:  Pediatrics       Date:  2011-06-06       Impact factor: 7.124

7.  Efficacy of selective mineralocorticoid and glucocorticoid agonists in canine septic shock.

Authors:  Caitlin W Hicks; Daniel A Sweeney; Robert L Danner; Peter Q Eichacker; Anthony F Suffredini; Jing Feng; Junfeng Sun; Ellen N Behrend; Steven B Solomon; Charles Natanson
Journal:  Crit Care Med       Date:  2012-01       Impact factor: 7.598

Review 8.  Endocrine dysfunction in sepsis: a beneficial or deleterious host response?

Authors:  Valeriu Gheorghiţă; Alina Elena Barbu; Monica Livia Gheorghiu; Florin Alexandru Căruntu
Journal:  Germs       Date:  2015-03-02

Review 9.  Updating the evidence for the role of corticosteroids in severe sepsis and septic shock: a Bayesian meta-analytic perspective.

Authors:  John L Moran; Petra L Graham; Sue Rockliff; Andrew D Bersten
Journal:  Crit Care       Date:  2010-07-13       Impact factor: 9.097

10.  Global utilization of low-dose corticosteroids in severe sepsis and septic shock: a report from the PROGRESS registry.

Authors:  Richard Beale; Jonathan M Janes; Frank M Brunkhorst; Geoffrey Dobb; Mitchell M Levy; Greg S Martin; Graham Ramsay; Eliezer Silva; Charles L Sprung; Benoit Vallet; Jean-Louis Vincent; Timothy M Costigan; Amy G Leishman; Mark D Williams; Konrad Reinhart
Journal:  Crit Care       Date:  2010-06-03       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.